Scarica l'app Stockscreener
0.00
100.00%
-13.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.60
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$17.96M
Reddito:
$40.93M
Utile/perdita netta:
$-23.82M
Rapporto P/E:
0.00
EPS:
-18.71
Flusso di cassa netto:
$-37.87M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$22.32
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
Nome
Pieris Pharmaceuticals Inc
Settore
Industria
Telefono
857-246-8998
Indirizzo
225 FRANKLIN STREET, BOSTON, MA
Confronta PIRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PIRS
Pieris Pharmaceuticals Inc
|
0.00 | 17.96M | 40.93M | -23.82M | -37.87M | -18.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Pieris Pharmaceuticals Inc Borsa (PIRS) Ultime notizie
TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor - ACCESS Newswire
Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease By Investing.com - Investing.com South Africa
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com - Defense World
Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada
Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com - Defense World
Twelve option delistings on December 23rd - TipRanks
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada
Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com
Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report
Pieris Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Julian Adams to its Board of Directors - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Claude Knopf as Senior Vice President and Chief Business Officer - Marketscreener.com
After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals
Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - The Manila Times
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent - The Bakersfield Californian
Palvella Therapeutics Announces Closing of Merger with - GlobeNewswire
Pieris Pharmaceuticals Announces Merger and Share Increase - TipRanks
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MyChesCo
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - The Eastern Progress Online
(PIRS) On The My Stocks Page - Stock Traders Daily
Pieris Pharmaceuticals announces board changes and merger update By Investing.com - Investing.com Nigeria
Pieris Pharmaceuticals announces board changes and merger update - Investing.com
(PIRS) Trading Report - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, ACNB, PIRS, OBDE on Behalf of Shareholders - The Malaysian Reserve
Comparing Evelo Biosciences (NASDAQ:EVLO) and Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
How To Trade (PIRS) - Stock Traders Daily
Lynx1 Capital Management LP Adjusts Stake in Pieris Pharmaceuticals Inc - GuruFocus.com
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
Pieris Pharmaceuticals Inc Azioni (PIRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
2.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):